AU2012343587B2 - Fertile transgenic animals useful for producing antibodies bearing human variable regions - Google Patents

Fertile transgenic animals useful for producing antibodies bearing human variable regions

Info

Publication number
AU2012343587B2
AU2012343587B2 AU2012343587A AU2012343587A AU2012343587B2 AU 2012343587 B2 AU2012343587 B2 AU 2012343587B2 AU 2012343587 A AU2012343587 A AU 2012343587A AU 2012343587 A AU2012343587 A AU 2012343587A AU 2012343587 B2 AU2012343587 B2 AU 2012343587B2
Authority
AU
Australia
Prior art keywords
mouse
human
heavy chain
antibody
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012343587A
Other languages
English (en)
Other versions
AU2012343587A1 (en
Inventor
Glenn A. Friedrich
E-Chiang Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45572821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012343587(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/310,431 external-priority patent/US20120204278A1/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of AU2012343587A1 publication Critical patent/AU2012343587A1/en
Application granted granted Critical
Publication of AU2012343587B2 publication Critical patent/AU2012343587B2/en
Priority to AU2016101604A priority Critical patent/AU2016101604B4/en
Priority to AU2016244295A priority patent/AU2016244295A1/en
Priority to AU2018217308A priority patent/AU2018217308A1/en
Priority to AU2021203905A priority patent/AU2021203905A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012343587A 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions Active AU2012343587B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2016101604A AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2018217308A AU2018217308A1 (en) 2011-12-02 2018-08-17 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2021203905A AU2021203905A1 (en) 2011-12-02 2021-06-11 Fertile transgenic animals useful for producing antibodies bearing human variable regions

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/310,431 US20120204278A1 (en) 2009-07-08 2011-12-02 Animal models and therapeutic molecules
US13/310,431 2011-12-02
GB1122047.2 2011-12-21
GBGB1122047.2A GB201122047D0 (en) 2011-12-21 2011-12-21 Transgenic animals
US13/416,684 US9447177B2 (en) 2009-07-08 2012-03-09 Transgenic mouse homozygous for chimeric IgH locus
US13/416,684 2012-03-09
PCT/GB2012/052956 WO2013079953A1 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2016101604A Division AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A Division AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions

Publications (2)

Publication Number Publication Date
AU2012343587A1 AU2012343587A1 (en) 2014-05-15
AU2012343587B2 true AU2012343587B2 (en) 2016-07-14

Family

ID=45572821

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012343587A Active AU2012343587B2 (en) 2011-12-02 2012-11-30 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016101604A Expired AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A Abandoned AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2018217308A Abandoned AU2018217308A1 (en) 2011-12-02 2018-08-17 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2021203905A Abandoned AU2021203905A1 (en) 2011-12-02 2021-06-11 Fertile transgenic animals useful for producing antibodies bearing human variable regions

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2016101604A Expired AU2016101604B4 (en) 2011-12-02 2016-09-12 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2016244295A Abandoned AU2016244295A1 (en) 2011-12-02 2016-10-13 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2018217308A Abandoned AU2018217308A1 (en) 2011-12-02 2018-08-17 Fertile transgenic animals useful for producing antibodies bearing human variable regions
AU2021203905A Abandoned AU2021203905A1 (en) 2011-12-02 2021-06-11 Fertile transgenic animals useful for producing antibodies bearing human variable regions

Country Status (11)

Country Link
US (2) US20130243759A1 (enExample)
EP (4) EP2649184B1 (enExample)
JP (4) JP2015502149A (enExample)
CN (1) CN104160031B (enExample)
AU (5) AU2012343587B2 (enExample)
BR (1) BR112014013121A2 (enExample)
CA (1) CA2857569A1 (enExample)
DE (1) DE202012013369U1 (enExample)
ES (1) ES2816899T3 (enExample)
GB (1) GB201122047D0 (enExample)
WO (1) WO2013079953A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
DK2813573T1 (da) * 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX378871B (es) 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
PT3501272T (pt) * 2013-03-13 2023-03-29 Regeneron Pharma Murganhos que expressam um repertório limitado de cadeia leve de imunoglobulina
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
US11160879B2 (en) 2014-01-15 2021-11-02 Masamichi Yamamoto Transgenic animal for visualization of ATP and use thereof
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA2944647C (en) 2014-04-03 2025-07-08 Igm Biosciences Inc MODIFIED J STRING
SG10201911411YA (en) * 2014-06-26 2020-02-27 Regeneron Pharma Methods and compositions for targeted genetic modifications and methods of use
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
KR20180132705A (ko) * 2016-04-04 2018-12-12 에테하 취리히 단백질 생산 및 라이브러리(Library) 생성을 위한 포유동물 세포주
KR102723182B1 (ko) * 2017-10-20 2024-10-31 프레드 허친슨 캔서 센터 선택된 항체를 발현하도록 유전자 변형된 b 세포를 생산하기 위한 시스템 및 방법
JP7420730B2 (ja) 2018-04-06 2024-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN118325896A (zh) * 2023-01-09 2024-07-12 上海交通大学医学院 一种抗体无功能等位基因小鼠模型及其构建方法和应用
TWI897189B (zh) 2023-01-18 2025-09-11 美商基利科學股份有限公司 具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
WO2025055311A1 (zh) * 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320448C2 (de) 1983-06-07 1986-09-04 Elasto-Press Schmitz GmbH, 3250 Hameln Mangelband für Wäschemangeln
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
BE1007904A3 (nl) 1993-12-23 1995-11-14 Dsm Nv Werkwijze voor de bereiding van een alkanol en/of een alkanon.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6077667A (en) 1996-06-26 2000-06-20 Bradley; Allan Method for chromosomal rearrangement by consecutive gene targeting of two recombination substrates to the deletion endpoints
US6355412B1 (en) 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
JP2003523899A (ja) * 2000-02-24 2003-08-12 参天製薬株式会社 製品ラベルからの汚染を防ぐための容器
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CN100526455C (zh) * 2001-12-21 2009-08-12 斯路姆-X股份有限公司 用于体外分离和培养具有种系传递能力的胚胎干细胞(es)细胞系的组合物
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
CN101802172A (zh) 2007-05-30 2010-08-11 通用医疗公司 由体细胞产生多能细胞的方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009076464A2 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
GB0915523D0 (en) 2009-09-07 2009-10-07 Genome Res Ltd Cells and methods for obtaining them
EP3417701B1 (en) 2009-10-06 2021-12-15 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
HUE068728T2 (hu) * 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
MX378871B (es) * 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
PL2809150T3 (pl) * 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL

Also Published As

Publication number Publication date
GB201122047D0 (en) 2012-02-01
CN104160031A (zh) 2014-11-19
AU2016244295A1 (en) 2016-11-03
EP4282879A3 (en) 2024-03-20
HK1185100A1 (zh) 2014-02-07
EP2649184B1 (en) 2015-10-07
DE202012013369U1 (de) 2016-08-23
AU2016101604B4 (en) 2016-11-24
JP2022159413A (ja) 2022-10-17
EP2989894B9 (en) 2022-12-14
US20130243759A1 (en) 2013-09-19
AU2016101604A4 (en) 2016-10-06
JP2020124228A (ja) 2020-08-20
CA2857569A1 (en) 2013-06-06
WO2013079953A1 (en) 2013-06-06
AU2018217308A1 (en) 2018-09-06
US20160353719A1 (en) 2016-12-08
EP3298889A1 (en) 2018-03-28
CN104160031B (zh) 2017-03-08
EP4282879A2 (en) 2023-11-29
BR112014013121A2 (pt) 2019-09-24
AU2012343587A1 (en) 2014-05-15
EP2649184A1 (en) 2013-10-16
JP2018038428A (ja) 2018-03-15
JP2015502149A (ja) 2015-01-22
AU2021203905A1 (en) 2021-07-08
EP2989894A1 (en) 2016-03-02
ES2816899T3 (es) 2021-04-06
EP2989894B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
AU2012343587B2 (en) Fertile transgenic animals useful for producing antibodies bearing human variable regions
JP6886002B2 (ja) ヒト化ユニバーサル軽鎖マウス
US20140331344A1 (en) Transgenic Animals
US20200205384A1 (en) Transgenic Animals
CN104202971B (zh) 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN104159444B (zh) 人源化的轻链小鼠
CN103429746B (zh) Adam6小鼠
GB2496375A (en) A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
RS67058B1 (sr) Miševi koji imaju modifikovani lambda laki lanac imunoglobulina i njihove upotrebe
US20140331339A1 (en) Transgenic Non-Human Assay Vertebrates, Assays and Kits
HK40103542A (en) Use of fertile transgenic animals for producing antibodies bearing human variable regions
DK2649184T3 (en) USE OF FERTILIZED TRANSGENE ANIMALS FOR THE MANUFACTURE OF ANTIBODIES CARRYING HUMAN VARIABLE REGIONS
HK1185100B (en) Use of fertile transgenic animals for producing antibodies bearing human variable regions
BR122023011479B1 (pt) Método para produzir uma proteína de ligação ao antígeno humano que se liga a um antígeno de interesse, método para produzir uma célula es animal não humana geneticamente modificada, método para modificar um locus de imunoglobulina de cadeia pesada de uma célula es de camundongo e método para produzir uma sequência de nucleotídeos que codifica uma cadeia leve de imunoglobulina totalmente humana

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)